Drug Discovery & DDS Weekly Report May 24, 2026

TIDES USA 2026: Oligonucleotide CMC Innovations Address Manufacturing and Analytical Bottlenecks

Eli Lilly’s Triple G-Agonist Retatrutide Succeeds in Two More Phase III Trials for Obesity and Type 2 Diabetes

Blood-Brain Barrier Drug Delivery Summit (B3DD) Convenes to Overcome CNS Therapeutic Hurdles

FDA Approves Sanofi’s Subcutaneous Isatuximab (Sarclisa Escena) for Multiple Myeloma, Enhancing Patient Convenience

FDA Approves Celcuity’s Breakthrough Gedatolisib for Advanced Breast Cancer with Priority Review Designation

Boehringer Ingelheim Initiates Phase II Trial for BI 3034701, a Potential First-in-Class Triple Receptor Agonist for Obesity

bioRxiv Preprint: TLS11a Aptamer-Functionalized LNP Platform for Hepatocyte-Preferential mRNA Delivery and CRISPR LDLR-KO Model Established

Eli Lilly Acquires AtaiBeckley to Accelerate Phase III Development of BPL-003 for Treatment-Resistant Depression and Mental Health